BioVest International, Inc.

BioVest International, Inc.

BioVest offers cell culture products, instruments, and related contract services to research institutions, biotech firms, and pharmaceutical companies. The company is also developing a therapeutic cancer vaccine for follicular non-Hodgkin's lymphoma that is customized for individual patient use. The candidate, dubbed BiovaxID, is undergoing late-stage clinical trials. Its AutovaxID product is a cell culture instrument designed to ease use of BiovaxID. BioVest is 76% owned by Accentia Biopharmaceuticals. Both BioVest and Accentia filed for Chapter 11 bankruptcy in 2008 and are restructuring their operations.

Contact Details

Office Address

BioVest International, Inc.
324 S. Hyde Park Ave., Suite 350
Tampa, FL, USA 33606
Phone: (813) 864-2558
Fax: (813) 258-6912

Executives

Chairman and CEO

Francis E. O'Donnell Jr.

President and General Counsel

Samuel S. (Sam) Duffey

Business Reviews for BioVest International, Inc.

Related Companies